HIMS Q3 Deep Dive: Personalized Offerings and Strategic Expansion Shape Telehealth Growth [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
On the other hand, next quarter's revenue guidance of $615 million was less impressive, coming in 2.6% below analysts' estimates. Its GAAP profit of $0.06 per share was 40.5% below analysts' consensus estimates. Is now the time to buy HIMS? Find out in our full research report (it's free for active Edge members). Hims & Hers Health (HIMS) Q3 CY2025 Highlights: Revenue: $599 million vs analyst estimates of $579.6 million (49.2% year-on-year growth, 3.3% beat) EPS (GAAP): $0.06 vs analyst expectations of $0.11 (40.5% miss) Adjusted EBITDA: $78.37 million vs analyst estimates of $68.04 million (13.1% margin, 15.2% beat) Revenue Guidance for Q4 CY2025 is $615 million at the midpoint, below analyst estimates of $631.6 million EBITDA guidance for the full year is $312 million at the midpoint, below analyst estimates of $316.9 million Operating Margin: 2%, down from 5.6% in the same quarter last year Customers: 2.47 million, up from 2.44 million in the previous quarter Ma
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health (NYSE:HIMS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
- Hims & Hers Continues Major International Expansion With Official Entry Into Canada [Yahoo! Finance]Yahoo! Finance
- A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity [Seeking Alpha]Seeking Alpha
- Humana And Mark Cuban's Cost Plus Drugs Working On Partnership To Lower Prices [Forbes]Forbes
- Hims & Hers Health, Inc. (HIMS): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- 11/25/25 - Form 4
- HIMS's page on the SEC website